Rituxan rituximab: Phase II results; marketed to treat non-Hodgkin's lymphoma

DNA said that in a U.S. Phase II trial in 21

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE